

ASH/FDA Workshop on Clinical Endpoints in Multiple Myeloma

Panel Members

Workshop Co-Chairs

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA

Richard Pazdur, MD
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring MD

Monoclonal Gammopathy of Unclear Significance (MGUS)

Subcommittee Chair: Robert A. Kyle, MD
Mayo Clinic
Rochester, MN

Geraldine P. Schechter, MD
Veterans Affairs Medical Center Washington
Washington, DC

Ann T. Farrell, MD
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring MD

Newly Diagnosed

Subcommittee Chair: S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN

Bart Barlogie, MD, PhD
Univ. of Arkansas for Medical Science
Little Rock, AR

Shastri, Kaushikkumar, MD
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring MD

J.F. San Miguel, MD, PhD
University of Salamanca.
Salamanca, Spain

Relapsed

Subcommittee Chair: Donna Weber, MD
M.D. Anderson Cancer Center
Houston, TX

Vicki L. Goodman, MD
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring MD

Sagar Lonial, MD
Emory University
Atlanta, GA

Robert Z. Orlowski, MD, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Refractory

Subcommittee Chair: Paul G. Richardson, MD
Dana Farber Cancer Institute
Boston, MA

Joan Blade, MD
Hospital Clinic of Barcelona
Barcelona, Spain

Edvardas Kaminskas, MD
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring MD

Donna Reece, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Maintenance

Subcommittee Chair: Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ

Peter F. Bross, MD
Center for Biologics Evaluation and Research
U.S. Food and Drug
Rockville MD

Nikhil C. Munshi, MD
Dana Farber Cancer Institute
Boston, MA

ASH Liaison

James N. George, MD
University of Oklahoma Health Sciences Center
Oklahoma City, OK

FDA Representative

Robert Kane, M.D
U.S. Food and Drug Administration
Silver Spring, MD

Industry Representative

Robert J. DeLap, MD, PhD
Celgene Corporation
Summit, NJ

NCI Representative

Donna Griebel, MD
Division of Cancer Prevention,
NCI, NIH
Rockville, MD

Patient Representatives

Bruce Holmberg
Rockville, MD

James L. Omel, MD
Grand Island, Nebraska

Statistician

John D. Crowley, PhD
Southwest Oncology Group Statistical Center
Seattle, WA

Rajeshwari Sridhara, PhD
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring, MD

Additional Workshop Subcommittee Members Not Serving as Panelists

Monoclonal Gammopathy of Unclear Significance (MGUS)

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, AZ

Newly Diagnosed

Mario Boccadoro, MD
University of Torino
Torino, Italy

Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY

Relapsed

Melissa Alsina, MD
H. Lee Moffitt Cancer Center
Tampa, FL

Brian G.M. Durie, MD
Cedars Sinai Outpatient Cancer Center
Los Angeles, CA

Refractory

William S. Dalton, MD, PhD
H. Lee Moffitt Cancer Center, The University of South Florida
Tampa, FL

Mohamad Hussein, MD
Cleveland Clinic
Cleveland, OH

Seema Singhal, MD
Northwestern University Medical. School
Chicago, IL

Maintenance

Jean-Luc Harousseau, MD
University Hospital Hôtel-Dieu
Nantes, France

G. David Roodman, MD
University of Pittsburgh
Pittsburgh, PA